Tacrolimus and cyclosporine A show similar efficacy in long-term survival and relapse reduction in AML post-transplant patients. No significant differences were found in leukemia-free survival, ...
RLS-0071 is an investigational peptide that has been shown to inhibit neutrophil-mediated inflammation. The Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations to ...
Posttransplant cyclophosphamide–containing prophylaxis correlated with lower aGVHD risk than tacrolimus/methotrexate, and ATG ...
MaaT Pharma to Present Four Abstracts at the 52nd EBMT Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on ...
Please provide your email address to receive an email when new articles are posted on . Greater fiber intake appeared linked to longer survival after allogeneic hematopoietic stem cell transplantation ...
Xervyteg demonstrated a 62% GI overall response rate at day 28, significantly exceeding historical controls, with durable responses and survival benefits over one year. The safety profile was ...
Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light. The ...
Editor's note: This article is part of the ASTCT Update blog. To read more from this blog, click here. For years now, transplant physicians have spoken different languages when referring to a matter ...
NORFOLK, Va .--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical mid-stage biotech company focused on harnessing the power of the immune system to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results